-

NanoTemper Brings Spectral Shift Technology to the Protein Production Market With Andromeda X, Enabling Biopharma and CROs to Increase Efficiency of Expression Screening for Recombinant Protein Targets

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--NanoTemper Technologies, well known for creating biophysical tools that accelerate the work of drug discovery researchers, brings their groundbreaking Spectral Shift technology to the protein production market with the release of Andromeda X, an instrument that determines optimal expression alongside thermal stability of recombinant proteins in crude lysates. Andromeda X increases the efficiency of protein production teams at Biopharma and CROs, who now have the ability to optimize purification schemes for challenging, low-yield targets much faster, and with unprecedented insights on thermal stability during expression screening.

“At NanoTemper, our vision of creating a world where every disease is treatable starts here, in early drug development. Without high-quality drug targets or protein therapeutics, researchers cannot realize this vision. So, we’ve adapted our reliable and trusted optics systems to provide valuable insights for those working to express and purify these critical targets,” says Dr. Philipp Baaske, co-CEO of NanoTemper.

Dr. Amit Gupta, Head of Product Management at NanoTemper, adds, “Andromeda X incorporates our Spectral Shift optics, which are precision engineered to be sensitive enough to reveal expression levels and stability characterization from small batch crude lysates before teams commit to a purification scheme. Andromeda X gives expression insights in less time than traditional SDS-PAGE gels and provides additional information on the foldedness and functionality of the recombinant proteins.”

With Andromeda X, protein production teams can now hand over high-quality recombinant proteins faster and save themselves the trouble of re-screening or chasing unpromising leads by assessing the stability of proteins early on. Andromeda provides all of the valuable information needed to help them quickly and efficiently select for conditions that result in expression of quality proteins.

Visit nanotempertech.com/andromeda to find out more details.

About NanoTemper Technologies

At NanoTemper, our vision is to help create a world where every disease is treatable. For us, that starts by equipping scientists with reliable biophysical tools that bring them the clarity, confidence, and momentum they need to discover and develop future therapies, even difficult ones. Because the path to a disease-free world requires courage, big thinking, and collaboration, we’ll continue to create innovative products that meet the needs of our customers as they face new and difficult challenges.

Contacts

John Valdez, Director of Marketing
john.valdez@nanotempertech.com
415.670.0424

NanoTemper Technologies



Contacts

John Valdez, Director of Marketing
john.valdez@nanotempertech.com
415.670.0424

Social Media Profiles
More News From NanoTemper Technologies

NanoTemper Technologies Launches Human Fc Labeling Kit, Accelerating Biologics Affinity Screening Workflows

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--NanoTemper Technologies, creator of high-quality, easy-to-learn biophysical tools for drug discovery, launches a new way for biologics researchers to screen humanized antibody therapeutics with the release of their Human Fc Labeling Kit. Optimized for use with Spectral Shift technology, an in-solution affinity screening method, scientists looking for innovative ways to accelerate candidate selection will appreciate the ability to measure affinities...

NanoTemper Technologies Unveils Biotinylated Target Labeling Kit, Empowering Scientists in Pharma Industry to Tackle Challenging Drug Targets

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--NanoTemper Technologies, creator of biophysical tools for drug discovery, today, proudly announced the launch of their highly anticipated Biotinylated Target Labeling Kit, expanding the molecular interaction analysis toolkit for scientists working with complex or undruggable targets, filling a vital gap in screening and hit validation workflows in the pharma industry. This new kit combined with NanoTemper’s exclusive Spectral Shift technology is the...

NanoTemper Technologies Announces Monolith X With Breakthrough Spectral Shift Technology, Enabling Binding Affinity Measurements Where Other Methods Fail

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--NanoTemper Technologies introduced Monolith X, adding breakthrough Spectral Shift technology to their top-selling Monolith product line, valued by scientists for easy setup of immobilization-free binding affinity measurements and minimal sample requirements. Monolith X combines two biophysical modalities — Spectral Shift and MST — equipping scientists to measure all types of binding interactions they encounter. “We hear from scientists that they are...
Back to Newsroom